In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how ...

For patients who have chronic lymphocytic leukemia (CLL), experiencing Richter transformation with central nervous system ...

Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...

In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia ...

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic ...

The regulator’s Office of Prescription Drug Promotion (OPDP) has already sent out two letters alleging “false or misleading” ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44 th ...

In the first Untitled Letter issued by the FDA in 2026, BeOne Medicines was critiqued for a DTC TV ad promoting its BTK ...

Erasca reported favorable safety and tolerability with no dose-limiting toxicities and predominantly low-grade adverse events across all dose levels. Initial Phase 1 monotherapy data for ERAS-0015 are ...

Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI ...

The NLIU-Trilegal National Article Writing & Presentation Competition on Labour & Employment Laws (NTC-LEL), 2026 is a ...

A man indecently exposed himself in a town park. It happened near the Claygate exit of Mote Park in Maidstone at around ...